DailyIQ
|
Sector:HealthcareAll sectors
Last updatedjust now

A·Agilent Technologies, Inc.

$150.85
+0.87 (+0.58%)
Overnight$150.86+0.01 (+0.01%)
High
$151.59
Open
$148.97
Market Cap
42.70B
52W High
$165.00
Low
$147.78
P. Close
$150.85
P/E
29.65
52W Low
$108.35
Fwd P/E
22.30
DailyIQ Est.
$178.16
Inst. Ownership
42.4%
Short Interest
1.83%
Days to Cover
3.8
Technical Score (1D)
55
BUY
News Sentiment
66
BULLISH
Agilent’s most recent earnings call, released 51 hours ago, confirmed a solid recovery in its life‑science tools segment, with recurring revenue strengthening and margins stabilizing, but a discounted‑cash‑flow analysis still flags the current valuation as potentially over‑extended. The company’s guidance for the fiscal year remains unchanged, so traders should monitor how the valuation gap narrows as the business continues to recover. A filing 63.5 hours ago for a debt shelf offering introduces uncertainty about future balance‑sheet leverage, though no immediate earnings impact is expected; the final terms will be key to assessing any potential dilution or refinancing risk. The launch of the Cary 635 FTIR spectrometer 67.7 hours ago signals continued investment in core product innovation, and early adoption rates will indicate whether this new instrument can lift revenue and margin in the diagnostics and life‑sciences segments. In the Q3 2026 results 89.9 hours ago, Agilent reported a 12 % jump in pharma revenue and a nearly 30 % rise in advanced therapeutics, exceeding analyst expectations and suggesting robust demand and pricing power. A second Q3 transcript 90.9 hours ago reiterated the company’s steady guidance and highlighted macro‑economic and currency risks, underscoring the need to watch for any shifts in the company’s capital allocation strategy. International revenue growth, noted 91.5 hours ago, outpaced domestic trends but remains modest in margin impact, so currency hedging and geopolitical developments will be important to track. The company’s 2026 revenue guidance was raised to $7.49–$7.51 billion 177 hours ago, with a fourth‑quarter outlook of $1.98–$2.00 billion, a move that has already spurred a 12 % 30‑day share‑price gain and a 27 % annual total shareholder return. Analysts across the board—Stifel, Citigroup, RBC, JP Morgan, Barclays, TD Cowen, Bernstein, and Goldman Sachs—have uniformly upgraded Agilent to Buy or Outperform and lifted price targets to $175–$190, reflecting confidence in the company’s earnings trajectory and product pipeline. Traders should watch for the next earnings release to confirm whether the company can sustain margin expansion and whether the debt shelf offering will be used to refinance existing debt or fund capital expenditures, as these factors will shape the short‑term trading range.
Earnings Summary
Agilent Technologies, a global provider of application-focused solutions for life sciences, diagnostics, and applied chemical markets, operates through Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets segments, positioning it within the healthcare diagnostics and research sector. In the most recent quarters, Agilent reported Q1 2025 revenue of $1.668B and Q2 2025 revenue of $1.738B, a 4.2% sequential increase, while EPS rose from $1.31 to $1.37, a 4.6% gain, both beating analyst expectations in each period. The company’s Q3 2025 revenue climbed to $1.861B, a 7.5% sequential rise, with EPS at $1.59, again surpassing estimates, indicating a consistent pattern of revenue acceleration and earnings beats over the last four quarters. Historically, Agilent has maintained double-digit revenue growth YoY, with EPS growth often outpacing revenue, reflecting effective cost control and margin expansion, particularly through its Ignite program. Recent news highlights a lift of FY 2026 revenue guidance to $7.49–$7.51B and a Q4 2026 revenue outlook of $1.98–$2.00B, driven by stronger third-quarter sales and robust demand in pharma, China, and applied markets; the company also launched the Cary 635 FTIR spectrometer, underscoring continued product innovation. Investors should watch for the Q4 2026 earnings announcement to confirm whether the upgraded guidance holds, monitor the progress of the Ignite cost-control initiative and any supply-chain disruptions that could affect margins, and track early adoption rates of new instruments such as the Cary 635, as these factors will be key to sustaining the current upside trajectory.

EPS

EstBeatMiss
$1.20$1.34$1.49$1.64$1.78Q1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.71 - -
Q2'26$1.44$1.49+3.8%
Q1'26$1.40$1.36-2.6%
Q3'25$1.58$1.59+0.4%
Q2'25$1.37$1.37+0.2%
Q1'25$1.26$1.31+3.6%

Revenue

EstBeatMiss
$1.6B$1.7B$1.8B$1.9B$2.0BQ1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.0B - -
Q2'26$1.8B$1.8B+0.0%
Q1'26$1.8B$1.8B-2.4%
Q3'25 - $1.9B -
Q2'25 - $1.7B -
Q1'25 - $1.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

A Stock Snapshot

HOLD55/100
$150.86+$0.01 (0.0%)
Market cap
42.70B
P/E ratio
29.6
Day range
$147.78 – $151.59
News sentiment
66/100 · Bullish
Analyst target
$174.90 (+15.9%)
Consensus
Buy · 32 analysts
52-week range+39.2% off low · -8.6% from high
$108.35$165.00
Price $150.86 DailyIQ Est. $178.16

A is in a holding pattern - neither trend nor momentum has taken control. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into A?

RICH

At today's price, Agilent Technologies, Inc. needs to grow free cash flow about 25.8% a year for the next 10 years to justify its valuation at a 9.27% cost of capital. Over its actual history it has compounded free cash flow at 4.7% a year, so the market is asking for 21.1 percentage points above its own delivered rate. On that basis A looks priced above what its own growth record supports.

Implied FCF growth
25.8%
Historical FCF CAGR
4.7%
Growth gap
+21.1 pts
Verdict
RICH
Discount rate (WACC)
9.27%
Beta
0.99

Behaviour On Record

What A's own history says about today's numbers

Realized volatility (21d)
33.7% 84th pct
Below its peak
-16.4%
vs 200-day average
+14.0%
Up days (1y)
52%

Agilent Technologies, Inc. is currently running 33.7% annualised volatility over the last 21 sessions. Measured against A's own 13 years of daily returns rather than a market-wide average, that is the 84th percentile — elevated for this stock, against a typical reading of 24.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

A is trading -16.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.2%, and the deepest was -38.2% in 2023. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +14.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 76th percentile — a somewhat wider gap than its own norm. Over the past year A closed higher on 52% of sessions, and it is currently 1 session into a falling streak.

On September specifically: over 13 years of records, A finished the month higher 6 of 13 times, with a median return of -0.2% and an average of +0.4%. Its strongest month historically has been November at +6.5% on average, its weakest February at -2.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: A has opened more than 2% away from the prior close in 114 of 3,267 sessions (3.5% of the time), with the largest gaps running +10.5% and -26.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, A moved an average of 3.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.2% and a largest of +9.4%.

All figures computed from 3,268 daily closes between 2013-09-05 and 2026-09-03, split-adjusted, recomputed daily. Percentiles are against A's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of A's sector?

Agilent Technologies, Inc. sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90

Options Market

What is the options market pricing for A?

CallsPuts

For Agilent Technologies, Inc.'s nearest expiry (2026-09-18, 13 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.52), with at-the-money implied volatility around 30.2%. The options market is pricing roughly a ±5.6% move by that expiry — a range of about $142.42–$159.30.

Put/call ratio (2026-09-18)
0.52
ATM implied volatility
30.2%
Total open interest
12,966
Expected move by 2026-09-18
±5.6% ($142.42–$159.30)

A Competitive Positioning

Agilent Technologies, Inc. (A) is tracked alongside these names in Diagnostics & Research on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

A is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.